Literature DB >> 16912858

[Glaucoma in the aged--barriers to understanding and compliance].

T S Dietlein1.   

Abstract

Glaucoma is a relatively common ocular disease among adults aged >65 years. However, knowledge about glaucoma, the physical capacity to perform self-application of antiglaucomatous drops, and general compliance may be massively restricted in the older population owing to significantly increasing comorbidity and other factors (e.g. their social and financial situation). Additional efforts by ophthalmologists, the pharmaceutical industry and health politics are required to improve knowledge and compliance among elderly glaucoma patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912858     DOI: 10.1007/s00347-006-1408-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  24 in total

1.  Practical problems with eye-drops among elderly ophthalmology outpatients.

Authors:  E Burns; G P Mulley
Journal:  Age Ageing       Date:  1992-05       Impact factor: 10.668

2.  Microprocessor controlled compliance monitor for eye drop medication.

Authors:  M M Hermann; M Diestelhorst
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

3.  Awareness about glaucoma and related eye health attitudes in Switzerland: a survey of the general public.

Authors:  Kaweh Mansouri; Selim Orgül; Frances Meier-Gibbons; André Mermoud
Journal:  Ophthalmologica       Date:  2006       Impact factor: 3.250

4.  Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication.

Authors:  Asif Salyani; Catherine Birt
Journal:  Can J Ophthalmol       Date:  2005-04       Impact factor: 1.882

5.  Longitudinal analysis of the relationship between regular eye examinations and changes in visual and functional status.

Authors:  Frank A Sloan; Gabriel Picone; Derek S Brown; Paul P Lee
Journal:  J Am Geriatr Soc       Date:  2005-11       Impact factor: 5.562

6.  The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire.

Authors:  T Odberg; J E Jakobsen; S J Hultgren; R Halseide
Journal:  Acta Ophthalmol Scand       Date:  2001-04

7.  Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices.

Authors:  Konstantin Gugleta; Selim Orgül; Josef Flammer
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

8.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

9.  Knowledge about glaucoma in the unselected population: a German survey.

Authors:  Norbert Pfeiffer; Günther K Krieglstein; Stefan Wellek
Journal:  J Glaucoma       Date:  2002-10       Impact factor: 2.503

10.  Compliance barriers in glaucoma: a systematic classification.

Authors:  James C Tsai; Cori A McClure; Sarah E Ramos; David G Schlundt; James W Pichert
Journal:  J Glaucoma       Date:  2003-10       Impact factor: 2.503

View more
  4 in total

1.  Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients.

Authors:  Christine M G Olthoff; Juliette G M M Hoevenaars; Bart W van den Borne; Carroll A B Webers; Jan S A G Schouten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-19       Impact factor: 3.117

2.  [Minimally invasive iridocorneal angle surgery].

Authors:  J F Jordan
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

3.  An exploratory study of factors influencing glaucoma treatment adherence.

Authors:  Jo Ellen Stryker; Allen Dale Beck; Susan A Primo; Katharina V Echt; Lucja Bundy; Grace Cho Pretorius; Karen Glanz
Journal:  J Glaucoma       Date:  2010-01       Impact factor: 2.503

4.  Trabectome surgery for primary and secondary open angle glaucomas.

Authors:  Jens F Jordan; Thomas Wecker; Christian van Oterendorp; Alexandra Anton; Thomas Reinhard; Daniel Boehringer; Matthias Neuburger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-26       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.